148 related articles for article (PubMed ID: 34431372)
1. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib.
Yılmaz A; Şimşek M; Hannarici Z; Büyükbayram ME; Bilici M; Tekin SB
Future Oncol; 2021 Nov; 17(33):4545-4559. PubMed ID: 34431372
[No Abstract] [Full Text] [Related]
2. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F; Dadduzio V; Tovoli F; Bertolini G; Cabibbo G; Cerma K; Vivaldi C; Faloppi L; Rizzato MD; Piscaglia F; Celsa C; Fornaro L; Marisi G; Conti F; Silvestris N; Silletta M; Lonardi S; Granito A; Stornello C; Massa V; Astara G; Delcuratolo S; Cascinu S; Scartozzi M; Casadei-Gardini A
PLoS One; 2020; 15(5):e0232449. PubMed ID: 32379785
[TBL] [Abstract][Full Text] [Related]
3. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
da Fonseca LG; Barroso-Sousa R; Bento Ada S; Blanco BP; Valente GL; Pfiffer TE; Hoff PM; Sabbaga J
Med Oncol; 2014 Nov; 31(11):264. PubMed ID: 25273866
[TBL] [Abstract][Full Text] [Related]
7. Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam.
Nguyen TTH; Nguyen VH; Nguyen VH; Nguyen TL; Le VQ
Cancer Control; 2019; 26(1):1073274819865269. PubMed ID: 31364390
[TBL] [Abstract][Full Text] [Related]
8. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Hatanaka T; Kakizaki S; Uehara D; Nagashima T; Ueno T; Namikawa M; Saito S; Hosonuma K; Suzuki H; Naganuma A; Takagi H; Sato K; Uraoka T
Intern Med; 2019 Jul; 58(13):1835-1844. PubMed ID: 30918170
[TBL] [Abstract][Full Text] [Related]
10. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
11. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
[TBL] [Abstract][Full Text] [Related]
12. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis.
Chen S; Shi M; Shen L; Qi H; Wan W; Cao F; Xie L; Wu Y; Chen G; Mo J; Zhu G; Ye D; Zhang Y; Feng Z; Xu L; Fan W
Int J Hyperthermia; 2020; 37(1):384-391. PubMed ID: 32323585
[No Abstract] [Full Text] [Related]
13. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Casadei Gardini A; Scarpi E; Faloppi L; Scartozzi M; Silvestris N; Santini D; de Stefano G; Marisi G; Negri FV; Foschi FG; Valgiusti M; Ercolani G; Frassineti GL
Oncotarget; 2016 Oct; 7(41):67142-67149. PubMed ID: 27613839
[TBL] [Abstract][Full Text] [Related]
14. The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer.
Hannarici Z; Yılmaz A; Buyukbayram ME; Turhan A; Çağlar AA; Bilici M; Tekin SB
Future Oncol; 2023 Feb; 19(4):315-325. PubMed ID: 37125596
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
Marasco G; Colecchia A; Bacchi Reggiani ML; Celsa C; Farinati F; Giannini EG; Benevento F; Rapaccini GL; Caturelli E; Di Marco M; Biasini E; Marra F; Morisco F; Foschi FG; Zoli M; Gasbarrini A; Baroni GS; Masotto A; Sacco R; Raimondo G; Azzaroli F; Mega A; Vidili G; Brunetto MR; Nardone G; Dajti E; Ravaioli F; Avanzato F; Festi D; Trevisani F;
Dig Liver Dis; 2021 Aug; 53(8):1011-1019. PubMed ID: 33353858
[TBL] [Abstract][Full Text] [Related]
16. Early decrease in serum amphiregulin or vascular endothelial growth factor levels predicts sorafenib efficacy in hepatocellular carcinoma.
Godin C; Bodeau S; Saidak Z; Louandre C; François C; Barbare JC; Coriat R; Galmiche A; Sauzay C
Oncol Rep; 2019 Mar; 41(3):2041-2050. PubMed ID: 30569112
[TBL] [Abstract][Full Text] [Related]
17. The Relationship between albumin-Bilirubin grade and survival in hepatocelluler carcinoma patients treated with sorefanib.
Fidan E; Fidan S; Merev E; Kazaz N
Niger J Clin Pract; 2022 Feb; 25(2):173-177. PubMed ID: 35170443
[TBL] [Abstract][Full Text] [Related]
18. A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma.
Zhou D; Zhang Y; Xu L; Zhou Z; Huang J; Chen M
Sci Rep; 2015 Oct; 5():15263. PubMed ID: 26486016
[TBL] [Abstract][Full Text] [Related]
19. Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis.
Yang HJ; Guo Z; Yang YT; Jiang JH; Qi YP; Li JJ; Li LQ; Xiang BD
World J Gastroenterol; 2016 Jun; 22(21):5088-95. PubMed ID: 27275101
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.
Orsi G; Tovoli F; Dadduzio V; Vivaldi C; Brunetti O; Ielasi L; Conti F; Rovesti G; Gramantieri L; Rizzato MD; Pecora I; Argentiero A; Teglia F; Lonardi S; Salani F; Granito A; Zagonel V; Marisi G; Cabibbo G; Foschi FG; Benevento F; Cucchetti A; Piscaglia F; Cascinu S; Scartozzi M; Casadei-Gardini A
Target Oncol; 2020 Dec; 15(6):773-785. PubMed ID: 33044683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
